X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PIRAMAL ENTERPRISES AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 17.9 36.5 48.9% View Chart
P/BV x 5.8 3.6 159.5% View Chart
Dividend Yield % 0.4 0.7 53.5%  

Financials

 AUROBINDO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
PIRAMAL ENTERPRISES
Mar-16
AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,5411,065 144.7%   
Low Rs582805 72.3%   
Sales per share (Unadj.) Rs237.5383.0 62.0%  
Earnings per share (Unadj.) Rs33.955.1 61.5%  
Cash flow per share (Unadj.) Rs40.674.1 54.8%  
Dividends per share (Unadj.) Rs2.5017.50 14.3%  
Dividend yield (eoy) %0.21.9 12.6%  
Book value per share (Unadj.) Rs120.6719.9 16.8%  
Shares outstanding (eoy) m585.17172.56 339.1%   
Bonus/Rights/Conversions PREF--  
Price / Sales ratio x4.52.4 183.1%   
Avg P/E ratio x31.317.0 184.6%  
P/CF ratio (eoy) x26.212.6 207.2%  
Price / Book Value ratio x8.81.3 677.6%  
Dividend payout %7.431.8 23.2%   
Avg Mkt Cap Rs m621,041161,344 384.9%   
No. of employees `00013.33.8 351.3%   
Total wages/salary Rs m15,50816,898 91.8%   
Avg. sales/employee Rs Th10,457.617,472.6 59.9%   
Avg. wages/employee Rs Th1,167.14,466.9 26.1%   
Avg. net profit/employee Rs Th1,491.62,512.8 59.4%   
INCOME DATA
Net Sales Rs m138,96166,099 210.2%  
Other income Rs m1,6632,425 68.6%   
Total revenues Rs m140,62468,524 205.2%   
Gross profit Rs m32,05618,723 171.2%  
Depreciation Rs m3,9263,274 119.9%   
Interest Rs m2,5689,388 27.4%   
Profit before tax Rs m27,2258,485 320.9%   
Minority Interest Rs m393 1,184.8%   
Prior Period Items Rs m01,593 0.0%   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m7,4441,032 721.4%   
Profit after tax Rs m19,8209,506 208.5%  
Gross profit margin %23.128.3 81.4%  
Effective tax rate %27.312.2 224.8%   
Net profit margin %14.314.4 99.2%  
BALANCE SHEET DATA
Current assets Rs m100,01547,488 210.6%   
Current liabilities Rs m74,759104,362 71.6%   
Net working cap to sales %18.2-86.0 -21.1%  
Current ratio x1.30.5 294.0%  
Inventory Days Days10741 264.4%  
Debtors Days Days11051 214.3%  
Net fixed assets Rs m52,35026,532 197.3%   
Share capital Rs m585345 169.6%   
"Free" reserves Rs m67,707114,024 59.4%   
Net worth Rs m70,567124,221 56.8%   
Long term debt Rs m8,47275,812 11.2%   
Total assets Rs m156,994308,356 50.9%  
Interest coverage x11.61.9 609.5%   
Debt to equity ratio x0.10.6 19.7%  
Sales to assets ratio x0.90.2 412.9%   
Return on assets %14.36.1 232.7%  
Return on equity %28.17.7 367.0%  
Return on capital %37.710.0 378.9%  
Exports to sales %51.017.2 296.9%   
Imports to sales %18.86.6 285.5%   
Exports (fob) Rs m70,92711,362 624.3%   
Imports (cif) Rs m26,1934,364 600.2%   
Fx inflow Rs m71,01514,435 492.0%   
Fx outflow Rs m28,7995,183 555.7%   
Net fx Rs m42,2169,253 456.2%   
CASH FLOW
From Operations Rs m17,596-67,773 -26.0%  
From Investments Rs m-13,801-8,768 157.4%  
From Financial Activity Rs m-19876,199 -0.3%  
Net Cashflow Rs m3,597-342 -1,050.5%  

Share Holding

Indian Promoters % 54.1 52.9 102.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 4.0 198.8%  
FIIs % 27.7 26.6 104.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 16.5 61.8%  
Shareholders   69,601 93,274 74.6%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  BIOCON LTD  J.B.CHEMICALS  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 23, 2017 03:36 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - FDC LTD. COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS